Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:32 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 13,729 matching trials from the live ClinicalTrials.gov search.
Filters: Baltimore, Maryland Clear all
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
215
States / cities
Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Not listed Phase 3 Interventional

ARISE - Aggressive Reduction of Inflammation Stops Events

NCT00066898
View directory record Official record
Conditions
Atherosclerosis, Coronary Artery Disease, Myocardial Infarction, Unstable Angina
Interventions
AGI-1067
Drug
Lead sponsor
AtheroGenics
Industry
Eligibility
18 Years and older
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
128
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 108 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2006 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 2 Interventional Results available

EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01118052
View directory record Official record
Conditions
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Interventions
Laboratory Biomarker Analysis, PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
Other · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
11
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Nov 1, 2026, 5:32 AM EST
Terminated Not applicable Interventional

Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy

NCT02541838
View directory record Official record
Conditions
Diabetes Complications, Diabetic Neuropathies
Interventions
Muscle power, balance perturbation, aerobic exercise
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
55 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Nov 1, 2026, 5:32 AM EST
Recruiting Not applicable Interventional

Effect of the HCC Liver-Link Intervention

NCT06728293
View directory record Official record
Conditions
HCC, Racial Disparities
Interventions
Liver Link
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults

NCT02601716
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, CHMI (7G8), CHMI (NF135.C10)
Biological
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 2 Interventional Results available

Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

NCT01055314
View directory record Official record
Conditions
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
Interventions
Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 49 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
121
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Nov 1, 2026, 5:32 AM EST
Recruiting No phase listed Observational

A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM

NCT06976606
View directory record Official record
Conditions
Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Interventions
Not listed
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Redwood City, California • Baltimore, Maryland • Columbia, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Nov 1, 2026, 5:32 AM EST
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

NCT05735184
View directory record Official record
Conditions
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Terminated Phase 3 Interventional Results available

Study of Tecovirimat for Human Mpox Virus

NCT05534984
View directory record Official record
Conditions
MPOX
Interventions
Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Completed Not applicable Interventional Results available

Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains

NCT02968758
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Comparison between GenePOC PCR and Reference Method
Device
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
Not listed
Enrollment
2,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Nov 1, 2026, 5:32 AM EST
Terminated Phase 3 Interventional Results available

A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

NCT05310071
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
130
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Nov 1, 2026, 5:32 AM EST
Active, not recruiting Phase 3 Interventional

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Ribociclib, Endocrine Therapy (ET)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
5,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
73
States / cities
Birmingham, Alabama • Goodyear, Arizona • Jonesboro, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Suspended Phase 3 Interventional

High Intensity Focused Ultrasound (HIFU) Ablation System Study

NCT00392106
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
propafenone, flecainide, dofetilide, sotolol, Pulmonary vein ablation, Amiodarone
Drug · Device
Lead sponsor
ProRhythm, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Fullerton, California • Los Angeles, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2008 · Synced Nov 1, 2026, 5:32 AM EST
Terminated Phase 2 Interventional Results available

Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT05237284
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
SAR443820, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 2 Interventional Results available

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

NCT02484430
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent Adult Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Nov 1, 2026, 5:32 AM EST
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women

NCT03196492
View directory record Official record
Conditions
Microbial Colonization
Interventions
No intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 24 Years · Female only
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Nov 1, 2026, 5:32 AM EST
Completed No phase listed Observational

The Mobility Toolkit: Electronically Augmented Assessment of Functional Recovery Following Lower-extremity Trauma

NCT04047030
View directory record Official record
Conditions
Gait
Interventions
None- Observational Study
Other
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 60 Years
Enrollment
244 participants
Timeline
2019 – 2024
U.S. locations
10
States / cities
Lexington, Kentucky • Baltimore, Maryland • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 1, 2026, 5:32 AM EST
Completed No phase listed Observational

Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer

NCT02856100
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F DCFPyL- Radiopharmaceutical
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Nov 1, 2026, 5:32 AM EST
Withdrawn Not applicable Interventional

Artemis Proximal Femoral Nail for Internal Fixation of Intertrochanteric Femur Fractures

NCT05559736
View directory record Official record
Conditions
Intertrochanteric Fractures, Femoral Fracture, Femoral Neck Fractures
Interventions
Artemis Proximal Femoral Nail (PFN) implant
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 2 Interventional Results available

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

NCT03836209
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
44
States / cities
Scottsdale, Arizona • Clovis, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge

NCT03040687
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC), B7A- CS6-expressing ETEC challenge strain
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 1 Interventional

Evaluating Patients With Varying Degrees of Renal Function

NCT00398307
View directory record Official record
Conditions
Renal Impairment
Interventions
S-1/Cisplatin
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
9
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Nov 1, 2026, 5:32 AM EST